ak109
mAbexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jun 6, 2020 (NCT04547205)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4802188 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06341335 | Phase 3 | Jun 19, 2024 | Akeso Pharmaceuticals, Inc., Peking University |
| NCT05142423 | Phase 1/Phase 2 (Phase 2) | Nov 3, 2021 | Akeso Pharmaceuticals, Inc., People's Liberation Army of China, Zhejiang University |
| NCT04982276 | Phase 1/Phase 2 (Phase 2) | Jul 20, 2021 | Akeso Pharmaceuticals, Inc., Chinese Academy of Medical Sciences |
| NCT04547205 | Phase 1 | Jun 6, 2020 | Akeso Pharmaceuticals, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 4 | 4 | 3 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2021 |
| Zhejiang University | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1